13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

Page 36 of 68

Page 36 of 68 – SEC Filing

EXHIBIT 6
to
SCHEDULE 13D
JOINT ACQUISITION STATEMENT
PURSUANT TO SECTION 240.13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
Dated:  April 18, 2017
/s/ Monica R. Landry
FARALLON CAPITAL MANAGEMENT, L.L.C.,
On its own behalf and
As the Manager of
AKUBRA INVESTORS, LLC,
BUSHRANGER FUNDING, LLC and
UTE HOLDINGS, LLC
By Monica R. Landry, Managing Member
/s/ Monica R. Landry
FARALLON PARTNERS, L.L.C.
By Monica R. Landry, Managing Member
/s/ Monica R. Landry
NGP, L.L.C.
By Farallon Capital Management, L.L.C., its Manager
By Monica R. Landry, Managing Member
/s/ Monica R. Landry
FARALLON AA GP, L.L.C.
By Monica R. Landry, Manager
/s/ Monica R. Landry
FARALLON PARTNERS GP VI, L.L.C.
By Monica R. Landry, Manager

Follow Nexvet Biopharma Plc (NASDAQ:NVET)

Page 36 of 68